PTCT PTC Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Jul 30, 2026
$63,46
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$61,23rendah 52m
$90,87tinggi 52m
Kapitalisasi Pasar (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Pendapatan (TTM)
$1.01B
lencana Anda
Rentang 52M
$61–$91
Peringkat Analis
BUY
Target Harga
$102
P/E
-117.5
ROE
20.6%
Margin Laba Bersih
-3.8%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
PTCT Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$63.46
Kapitalisasi Pasar (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Pendapatan (TTM)
$1.01B
ROE (TTM)
20.6%
D/E Utang/Ekuitas (MRQ)
-3.6
Rentang 52M
$61–$91
PTCT Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Tentang PTC Therapeutics, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
karyawan991
negaraUS
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$1.73B2016-12-31 → 2025-12-31
EPS$7.782019-12-31 → 2025-12-31
Arus Kas Bebas$702M2016-12-31 → 2025-12-31
Margin bersih-3.8%2016-12-31 → 2025-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | PTCT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | -117.5rata-rata 5T ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.2rata-rata 5T ≈3.8 | ≈3.8 | 55.0 | Kurang nilai | |
| P/B (MRQ) | -32.0rata-rata 5T ≈481.5 | ≈481.5 | · | · | |
| EV / EBITDA (TTM) | 20.2rata-rata 5T ≈-5.5 | ≈-5.5 | · | · | |
| Harga / FCF (TTM) | -133.2rata-rata 5T ≈-10.8 | ≈-10.8 | · | · | |
| Harga / Arus Kas (TTM) | -173.4rata-rata 5T ≈-12.1 | ≈-12.1 | · | · | |
| EV / Pendapatan (TTM) | 3.6rata-rata 5T ≈3.0 | ≈3.0 | · | · | |
| EV / FCF (TTM) | -91.9rata-rata 5T ≈-8.4 | ≈-8.4 | · | · | |
| Harga / Nilai Buku Berwujud (MRQ) | -9.3 | · | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | PTCT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | 12.5%rata-rata 5T ≈-25.9% | ≈-25.9% | -24.1% | Tingkat teratas | |
| Margin EBITDA (TTM) | 17.9%rata-rata 5T ≈-13.8% | ≈-13.8% | -24.1% | Tingkat teratas | |
| Margin Sebelum Pajak (TTM) | -6.6%rata-rata 5T ≈-43.8% | ≈-43.8% | -28.9% | Tingkat teratas | |
| Margin Laba Bersih (TTM) | -3.8%rata-rata 5T ≈-42.4% | ≈-42.4% | -38.1% | Tingkat teratas | |
| ROA (TTM) | -1.3%rata-rata 5T ≈-12.6% | ≈-12.6% | -27.7% | Tingkat teratas | |
| ROE (TTM) | 20.6%rata-rata 5T ≈-299.7% | ≈-299.7% | -40.8% | Lemah | |
| ROIC | 1044.7%rata-rata 5T ≈267.1% | ≈267.1% | -37.7% | Tingkat teratas |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | PTCT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Utang / Ekuitas (MRQ) | -3.6rata-rata 5T ≈74.5 | ≈74.5 | · | · | |
| Rasio Lancar (MRQ) | 3.4rata-rata 5T ≈2.1 | ≈2.1 | 8.3 | Likuiditas rendah | |
| Rasio Cepat (MRQ) | 3.2rata-rata 5T ≈2.0 | ≈2.0 | 3.2 | Sejajar | |
| Utang Jangka Panjang / Ekuitas (MRQ) | -3.2rata-rata 5T ≈65.1 | ≈65.1 | · | · |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | PTCT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 114.5%rata-rata 5T ≈41.2% | ≈41.2% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | 35.3%rata-rata 5T ≈28.3% | ≈28.3% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 35.4% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | PTCT | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.8rata-rata 5T ≈0.5 | ≈0.5 | 0.4 | Tingkat teratas | |
| Receivables Turnover (Perputaran Piutang) | 10.2rata-rata 5T ≈6.8 | ≈6.8 | 9.7 | Sejajar | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$1.7M | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
105.2%
Laporan Berikutnya
Nov 02, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 5, 2026 | $0.92 | $0.43 | 116.4% |
| 31 Maret 2026 | $-0.03 | $-0.48 | 93.7% | |
| 31 Des. 2025 | $-1.67 | $0.04 | -4460.3% | |
| 30 Sep. 2025 | $0.20 | $-1.40 | 114.3% | |
| 30 Juni 2025 | $-0.83 | $-1.08 | 23.3% | |
| 31 Maret 2025 | $10.04 | $-0.22 | 4743.8% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-2.52 | $-14.13 | $-10.81 | · | $0.02 | $6.91 | $9.60 | $6.93 | $3.76 | $3.50 | $6.66 | $9.07 | |
| Revenue / Share | $19.60 | $10.50 | $12.53 | · | $7.64 | · | · | · | · | · | · | $0.80 | |
| Cash Flow / Share | $8.05 | $-1.40 | $-2.12 | · | $-3.57 | · | · | · | · | · | · | $-1.81 | |
| Cash / Share | $12.09 | $10.03 | $7.85 | · | $2.68 | $3.00 | $4.65 | $3.35 | $2.69 | $1.71 | $1.71 | $1.51 | |
| EPS (TTM) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-3.21 | $-3.21 | $-3.21 | $-3.21 | $-2.97 |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | · | 78,471,119 | 78,151,240 | 78,115,836 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | · | 87,115,369 | 78,151,240 | 86,385,922 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.98 | $-2.18 | · | $-1.95 | $-2.60 | $-2.34 | · | $-13.70 | $-12.75 | $-11.66 | · | $-8.89 | $-7.69 | $-6.18 | · | $-3.16 | |
| Revenue / Share | $3.92 | $3.30 | · | $2.42 | $2.29 | $13.61 | · | $2.56 | $2.43 | $2.75 | · | $2.61 | $2.86 | $2.99 | · | $3.03 | |
| Cash Flow / Share | · | $-0.72 | · | · | · | $10.07 | · | · | · | $0.93 | · | · | · | $-0.40 | · | · | |
| Cash / Share | $12.60 | $10.06 | · | $8.41 | $12.82 | $18.68 | · | $6.84 | $8.51 | $7.15 | · | $2.19 | $2.77 | $2.26 | · | $1.45 | |
| EPS (TTM) | $-0.54 | $-2.29 | · | $8.56 | $6.97 | $6.51 | · | $-5.95 | $-6.32 | $-7.69 | · | $-8.65 | $-8.42 | $-7.89 | · | $-7.47 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.01B | $827M | · | $1.78B | $1.76B | $1.77B | · | $901M | $900M | $928M | · | $798M | $819M | $770M | · | $697M | |
| Net Income TTM | $-38M | $-187M | · | $752M | $629M | $595M | · | $-453M | $-480M | $-579M | · | $-642M | $-618M | $-571M | · | $-531M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | -151.1 | -29.8 | · | 7.2 | 7.0 | 7.8 | · | -6.2 | -4.8 | -3.8 | · | -2.6 | -4.8 | -6.1 | · | -6.7 | |
| P/S | 6.7 | 6.8 | · | 2.8 | 2.2 | 2.3 | · | 3.2 | 2.6 | 2.4 | · | 2.1 | 3.7 | 4.7 | · | 5.2 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| EV / Revenue | 5.1 | 4.9 | · | 2.0 | 1.2 | 1.3 | · | 2.4 | 1.7 | 1.8 | · | 2.5 | 4.0 | 5.0 | · | 5.2 | |
| Earnings Yield | -0.66% | -3.4% | · | 14.0% | 14.3% | 12.8% | · | -16.0% | -20.7% | -26.4% | · | -38.6% | -20.7% | -16.3% | · | -14.9% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $1.73B | $807M | $938M | $699M | $539M |
| Margin Operasi % | 50.1% | -37.5% | -46.9% | · | -69.5% |
| Laba Bersih | $683M | $-363M | $-627M | $-559M | $-524M |
| EPS Dilusian | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Utang / Ekuitas | -1.4 | -0.3 | -0.3 | · | 300.0 |
| Rasio Lancar | 2.3 | 2.4 | 2.0 | · | 1.9 |
| Rasio Cepat | 2.2 | 2.2 | 1.7 | · | 1.7 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $702M | $-114M | $-187M | · | $-280M |
Pemilik institusional (13F) 403 pengaju · $8.6B total · Per tanggal 30 Sep. 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
403
Nilai yang dipegang
$8.6B
Posisi baru
76
Posisi yang keluar
43
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 76 (+7 vs Kuartal sebelumnya) | 43 (-7 vs Kuartal sebelumnya) | 140 (+3 vs Kuartal sebelumnya) | 114 (+10 vs Kuartal sebelumnya) | -1.4M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| BlackRock, Inc. | $1.139.088.671 | 13.964.554 | 13,21% | Saham |
| VANGUARD GROUP INC | $668.691.300 | 8.803.203 | 7,75% | Saham |
| RTW INVESTMENTS, LP | $631.875.072 | 7.746.415 | 7,33% | Saham |
| JANUS HENDERSON GROUP PLC | $489.997.100 | 7.193.433 | 5,68% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401.986.014 | 4.928.111 | 4,66% | Saham |
| STATE STREET CORP | $375.136.515 | 4.598.952 | 4,35% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $336.743.228 | 4.128.273 | 3,90% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $305.000.589 | 3.739.127 | 3,54% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $180.089.116 | 2.207.376 | 2,09% | Saham |
| TORONTO DOMINION BANK | $176.668.031 | 2.165.846 | 2,05% | Saham |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159.563.645 | 1.956.156 | 1,85% | Saham |
| Hood River Capital Management LLC | $141.818.662 | 1.738.613 | 1,64% | Saham |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140.519.660 | 1.722.688 | 1,63% | Saham |
| D. E. Shaw & Co., Inc. | $126.345.323 | 1.548.919 | 1,47% | Saham |
| TANG CAPITAL MANAGEMENT LLC | $122.355.000 | 1.500.000 | 1,42% | Saham |
| BANK OF AMERICA CORP /DE/ | $118.462.234 | 1.452.277 | 1,37% | Saham |
| Driehaus Capital Management LLC | $117.469.528 | 1.440.107 | 1,36% | Saham |
| FMR LLC | $114.056.206 | 1.398.261 | 1,32% | Saham |
| Jefferies Financial Group Inc. | $110.693.916 | 1.357.042 | 1,28% | Saham |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94.361.749 | 1.156.819 | 1,09% | Saham |
| Pictet Asset Management Holding SA | $93.629.635 | 1.147.844 | 1,09% | Saham |
| MORGAN STANLEY | $90.026.886 | 1.103.675 | 1,04% | Saham |
| ARMISTICE CAPITAL, LLC | $87.393.690 | 1.071.395 | 1,01% | Saham |
| Blue Sparrow, LLC /DE | $85.705.599 | 1.050.700 | 0,99% | Saham |
| FRANKLIN RESOURCES INC | $83.799.082 | 1.027.327 | 0,97% | Saham |
| Invesco Ltd. | $76.804.761 | 941.581 | 0,89% | Saham |
| Palo Alto Investors LP | $74.950.268 | 918.846 | 0,87% | Saham |
| NORTHERN TRUST CORP | $71.783.966 | 880.029 | 0,83% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64.449.436 | 790.112 | 0,75% | Saham |
| CITADEL ADVISORS LLC | $60.999.840 | 747.822 | 0,71% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $59.015.895 | 723.500 | 0,68% | Saham |
| Boston Partners | $58.606.553 | 718.574 | 0,68% | Saham |
| JUPITER ASSET MANAGEMENT LTD | $57.706.697 | 707.450 | 0,67% | Saham |
| MARSHALL WACE, LLP | $57.489.476 | 704.787 | 0,67% | Saham |
| JPMORGAN CHASE & CO | $56.073.502 | 684.042 | 0,65% | Saham |
| ARMISTICE CAPITAL, LLC | $53.836.200 | 660.000 | 0,62% | Opsi beli |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53.377.940 | 654.382 | 0,62% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $52.017.434 | 637.704 | 0,60% | Saham |
| GOLDMAN SACHS GROUP INC | $50.430.408 | 618.247 | 0,58% | Saham |
| LOOMIS SAYLES & CO L P | $48.156.807 | 590.374 | 0,56% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $47.953.943 | 587.887 | 0,56% | Saham |
| Nuveen, LLC | $47.622.931 | 583.829 | 0,55% | Saham |
| Bank of New York Mellon Corp | $45.145.865 | 553.462 | 0,52% | Saham |
| PRINCIPAL FINANCIAL GROUP INC | $44.181.166 | 541.635 | 0,51% | Saham |
| VOYA INVESTMENT MANAGEMENT LLC | $43.992.251 | 539.319 | 0,51% | Saham |
| Ensign Peak Advisors, Inc | $41.442.128 | 508.056 | 0,48% | Saham |
| AMERICAN CENTURY COMPANIES INC | $40.866.277 | 500.995 | 0,47% | Saham |
| FEDERATED HERMES, INC. | $39.432.896 | 483.424 | 0,46% | Saham |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36.050.432 | 441.957 | 0,42% | Saham |
| Parkman Healthcare Partners LLC | $35.539.315 | 435.691 | 0,41% | Saham |
Aktivis & pemilik 5%+ 3 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 pengajuan | 30 Jan. 2015 | · | Pengajuan awal | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 pengajuan | 12 Nov. 2014 | · | Pengajuan awal | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 5 Juli 2013 | · | Pengajuan awal | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 37 orang dalam · 15 pejabat · 20 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | 4 Agu 2026 S | 383.868 | 0 | 13 | $-4.219.888 |
| Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER | 31 Jan. 2023 S | 54.903 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14 Juli 2026 S | 83.986 | 0 | 3 | $-652.864 |
| Emily Luisa Hill | CHIEF FINANCIAL OFFICER | 27 Maret 2023 S | 38.925 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 9 Mei 2017 M | 37.850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15 Jan. 2015 M | 39.247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10 Feb. 2020 M | 6.744 | 0 | 0 | $0 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 17 Agu 2026 M | 105.272 | 0 | 63 | $-5.955.553 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 9 Juli 2026 M | 60.299 | 0 | 62 | $-25.989.291 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17 Juni 2026 M | 70.199 | 0 | 5 | $-1.941.426 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10 Juni 2026 S | 73.411 | 0 | 28 | $-7.477.160 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 2 April 2026 S | 79.115 | 0 | 6 | $-1.081.515 |
| Mark Rothera | Chief Commercial Officer | 24 Mei 2017 M | 33.739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 3 Jan. 2017 A | 6.000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 4 Jan. 2016 A | 3.239 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | Direktur | 30 Sep. 2026 M | 22.500 | 0 | 2 | $-1.698.120 |
| Michael Schmertzler | Direktur | 17 Sep. 2026 S | 1.296.594 | 0 | 16 | $-6.313.453 |
| Hege Elisabeth Sollie-Zetlmayer | Direktur | 28 Juli 2026 A | 52.526 | 0 | 0 | $0 |
| Mary L. Smith | Direktur | 9 Juli 2026 M | 21.813 | 0 | 2 | $-1.425.060 |
| Jessica Caroline Chutter | Direktur | 24 Maret 2026 A | 7.333 | 0 | 0 | $0 |
| Stephanie Okey | Direktur | 10 Maret 2026 M | 8.000 | 0 | 3 | $-1.463.076 |
| Emma Reeve | Direktur | 5 Jan. 2026 M | 10.666 | 0 | 15 | $-4.229.530 |
| Alethia Young | Direktur | 2 Jan. 2026 A | 21.067 | 0 | 0 | $0 |
| Allan Steven Jacobson | Direktur | 2 Jan. 2026 A | 21.451 | 0 | 11 | $-2.912.018 |
| Jerome B Zeldis | Direktur | 2 Jan. 2026 A | 22.500 | 0 | 0 | $0 |
| William F. Bell Jr. | Direktur | 15 Feb. 2024 A | 10.333 | 0 | 0 | $0 |
| Dawn Svoronos | Direktur | 9 Juni 2022 S | 29.017 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Direktur | 3 Jan. 2017 A | · | 0 | 0 | $0 |
| Adam Koppel | Direktur | 3 Jan. 2017 A | 2.333.333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Direktur | 3 Jan. 2017 A | · | 0 | 0 | $0 |
| Richard Aldrich | Direktur | 8 Juni 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Direktur | 16 Maret 2015 S | 2.242 | 0 | 0 | $0 |
| Axel Bolte | Direktur | 25 Juni 2013 P | 20.000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | Pemilik 10% | 17 Des. 2013 S | 2.441.504 | 0 | 0 | $0 |
| David P Southwell | · | 2 Jan. 2026 A | 20.850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | · | 28 April 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | · | 25 Juni 2013 C | 2.256.882 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 68 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,74% | 4.145 SH | 11 Sep. 2026 | Harian |
| PSCH · Invesco Exchange-Traded Fund Trust … | 2,93% | 79.357 SH | 2 Okt. 2026 | Harian |
| PBE · Invesco Exchange-Traded Fund Trust | 2,47% | 159.717 SH | 2 Okt. 2026 | Harian |
| MEDI · Harbor ETF Trust | 1,31% | 7.913 NS | 31 Juli 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,25% | 18.062 NS | 31 Juli 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,23% | 22.852 SH | 2 Okt. 2026 | Harian |
| JSML · Janus Detroit Street Trust | 1,03% | 54.825 NS | 31 Juli 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,94% | 145.033 NS | 31 Juli 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98.733 SH | 19 Agu 2026 | Harian |
| VAMO · Cambria ETF Trust | 0,72% | 11.494 NS | 31 Juli 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 0,71% | 5.120 NS | 31 Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,63% | 46.006 NS | 31 Juli 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,49% | 658 NS | 31 Juli 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,42% | 3.031 NS | 31 Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,40% | 613.266 SH | 11 Sep. 2026 | Harian |
| BRNY · EA Series Trust | 0,39% | 33.006 NS | 31 Juli 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290.018 SH | 19 Agu 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,36% | 5.891 SH | 2 Okt. 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75.795 SH | 19 Agu 2026 | Harian |
| ESSC · Strategy Shares | 0,34% | 1.785 NS | 31 Juli 2026 | N-PORT |
| IWO · iShares Trust | 0,31% | 664.357 SH | 11 Sep. 2026 | Harian |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,27% | 22.505 NS | 31 Juli 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 25.676 NS | 31 Juli 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,24% | 3.125 NS | 31 Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477.030 SH | 19 Agu 2026 | Harian |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,19% | 19.797 NS | 31 Juli 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3.667 NS | 31 Juli 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1.099.640 SH | 19 Agu 2026 | Harian |
| IWM · iShares Trust | 0,18% | 2.118.779 SH | 11 Sep. 2026 | Harian |
| RSSL · Global X Funds | 0,18% | 39.691 NS | 31 Juli 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,18% | 629 NS | 31 Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,16% | 23.005 SH | 11 Sep. 2026 | Harian |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 65.468 SH | 2 Okt. 2026 | Harian |
| LRGF · iShares Trust | 0,16% | 84.774 SH | 11 Sep. 2026 | Harian |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35.428 SH | 19 Agu 2026 | Harian |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 51.459 NS | 31 Juli 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,14% | 18.636 NS | 31 Juli 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,13% | 5.320 SH | 2 Okt. 2026 | Harian |
| FBUF · Fidelity Greenwood Street Trust | 0,12% | 413 NS | 31 Juli 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3.600 NS | 31 Juli 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,10% | 224.327 NS | 31 Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 952.071 SH | 19 Agu 2026 | Harian |
| VB · VANGUARD INDEX FUNDS | 0,08% | 1.902.509 SH | 19 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,08% | 211.842 SH | 19 Agu 2026 | Harian |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 6.756 NS | 31 Juli 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 33.487 NS | 31 Juli 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,06% | 12.627 NS | 31 Juli 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,06% | 18.932 SH | 2 Okt. 2026 | Harian |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,06% | 10.557 SH | 19 Agu 2026 | Harian |
| ESML · iShares Trust | 0,06% | 22.893 SH | 11 Sep. 2026 | Harian |
| WSML · iShares Trust | 0,04% | 4.360 SH | 11 Sep. 2026 | Harian |
| TILT · FlexShares Trust | 0,01% | 4.108 NS | 31 Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2.636.335 SH | 19 Agu 2026 | Harian |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 66.405 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 6.819 SH | 19 Agu 2026 | Harian |
| ESGV · VANGUARD WORLD FUND | 0,01% | 18.275 SH | 19 Agu 2026 | Harian |
| ITOT · iShares Trust | 0,01% | 109.219 SH | 11 Sep. 2026 | Harian |
| IWV · iShares Trust | 0,01% | 22.686 SH | 10 Sep. 2026 | Harian |
| DFAC · Dimensional ETF Trust | 0,01% | 43.296 NS | 31 Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1.090 NS | 31 Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 284 NS | 31 Juli 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 249 NS | 31 Juli 2026 | N-PORT |
| IJR · iShares Trust | · | 5.061.986 SH | 10 Sep. 2026 | Harian |
| IJT · iShares Trust | · | 784.746 SH | 9 Sep. 2026 | Harian |
| IWN · iShares Trust | · | 114.658 SH | 11 Sep. 2026 | Harian |
| XJR · iShares Trust | · | 11.464 SH | 31 Agu 2026 | Harian |
| ISCB · iShares Trust | · | 3.281 SH | 11 Sep. 2026 | Harian |
| SMLF · iShares Trust | · | 64.380 SH | 11 Sep. 2026 | Harian |
PTCT Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 21 analis
BELI
Target median
$101.00
+59,2%
6 28,6%
Beli Kuat
11 52,4%
Beli
3 14,3%
Tahan
1 4,8%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
14 analis · 2026-10-01Target rata-rata $101.79 +60,4%
← Di bawah semua target
Harga saat ini $63.46
Rendah$70.00
Rata-rata$101.79
Tinggi$137.00
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | · |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | · |
| ERAS | $1.06B | -8.5 | · | · | -35.7% | · |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | · |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | · |
Sinyal Perdagangan Sinyal beli/jual terbaru dengan harga masuk dan rasio risiko/imbalan
Tidak ada sinyal terbuka saat ini — tidak ada kartu yang terisi, dan itu jujur.
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Jul 30, 2026